Valneva SE (NASDAQ:VALN) Sees Significant Decline in Short Interest

Valneva SE (NASDAQ:VALN) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 14,500 shares, a drop of 69.9% from the October 31st total of 48,200 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 20,100 shares, the short-interest ratio is currently 0.7 days.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC grew its holdings in shares of Valneva SE (NASDAQ:VALN) by 42.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,252 shares of the company’s stock after purchasing an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.13% of Valneva worth $649,000 at the end of the most recent reporting period. 11.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reduced their target price on shares of Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

Valneva Trading Up 2.3 %

Shares of Valneva stock traded up $0.09 during mid-day trading on Friday, hitting $4.05. 24,890 shares of the stock were exchanged, compared to its average volume of 12,719. Valneva has a 12 month low of $3.91 and a 12 month high of $11.96. The company has a 50-day simple moving average of $5.49 and a 200 day simple moving average of $6.85. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.